Pablo Corral: The Truth About Very Low LDL-Cholesterol
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn about a recent article by Luz Clemencia Zárate-Correa et al., published in Atherosclerosis, adding:
”Our last manuscript is out.
‘Safety of Very Low LDL-Cholesterol:
Ten Common Concerns, Misconceptions, and Evidence-Based Clarifications’
Very low LDL-C levels continue to generate debate, fear, and misinformation in clinical practice.
In this review, we critically examined 10 of the most frequent concerns related to intensive LDL-C lowering:
- Cognitive decline
- Hemorrhagic stroke
- Cancer
- Cataracts
- Hormonal dysfunction
- Diabetes risk
- Muscle symptoms
- Older adults
- Sex differences
- Overall cardiovascular benefit
The key message is clear:
RCTs, meta-analyses, and genetic evidence consistently support the safety profile of very low achieved LDL-C levels in appropriately selected high-risk patients.
- Some adverse effects are real — particularly statin-associated dysglycemia and muscle symptoms — but their absolute risk is generally modest compared with the magnitude of ASCVD risk reduction.
- Therapeutic inertia and misinformation remain major barriers in preventive cardiology. Evidence-based communication matters.
- Lower LDL-C. Earlier. Longer. Safer than many still believe.
Proud to collaborate with outstanding colleagues from Latin America, Europe, and beyond in this international effort.”
Title: Safety of Very Low LDL-Cholesterol: Ten Common Concerns, Misconceptions, and Evidence-Based Clarifications
Authors: Luz Clemencia Zárate-Correa, Ángel García-Peña, Sergio Emanuel Kaiser, Carlos A. Aguilar-Salinas, Máxima Mendez-Castillo, Roopa Mehta, Cynthia M. Valerio, Rodrigo O. Moreira, Leonardo G. Mancillas-Adame, José Antonio Cetina Canto, Juan José Parcero, Ximena Reyes, Meral Kayikcioglu, Alexandros D. Tselepis, Laura Schreier, Pablo Corra
Other featuring Pablo Corral on Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy